The IDEA team will help guide Candel’s commercial strategy development and support the Company’s commercial projects related to CAN-2409. Through this partnership, Candel will gain access to a ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in ...

Hall et al. show that p53 can influence the timing of virus-induced CPE at a single multiplicity of infection in cancer cell lines. Is this conclusion at odds with data from other groups, or with ...

HELSINKI and NAPLES, Italy and PERTH, Australia, March 10, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy announces that it has successfully ...

There's no additional replication in the person ... Morgon says that CanSinoBIO chose to use adenovirus five because it's a well-known pathogen and has never been associated with cardiovascular ...

Currently, replication-deficient adenovirus vectors and poxvirus vectors are widely used in vaccine R&D for a variety of infectious diseases in humans and animals, including AIDS, hepatitis B, ...

NEEDHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...

The global burden of cervical cancer is highest in low- and middle-income countries (LMICs). Women living with HIV infection are particularly impacted by cervical cancer despite availability and ...